The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent

Christopher Bachran, Matthias Schröder, Lena Conrad, Juan J. Cragnolini, Fikadu Tafesse, Laura Helming, Hidde L. Ploegh, Lee Kim Swee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The central role of myeloid cells in driving autoimmune diseases and cancer has raised interest in manipulating their function or depleting them for therapeutic benefits. To achieve this, antibodies are used to antagonize differentiation, survival and polarization signals or to kill target cells, for example in the form of antibody-drug conjugates (ADC). The action of ADC in vivo can be hard to predict based on target expression pattern alone. The biology of the targeted receptor as well as its interplay with the ADC can have drastic effects on cell apoptosis versus survival. Here we investigated the efficacy of CD11b or Ly-6C/Ly-6G-specific variable fragments of camelid heavy chain-only antibodies (VHH) conjugated to Pseudomonas exotoxin A to deplete myeloid cells in vitro and in vivo. Our data highlight striking differences in cell killing in vivo, depending on the cell subset and organs targeted, but not antigen expression level or VHH affinity. We observed striking differences in depletion efficiency of monocytes versus granulocytes in mice. Despite similar binding of Ly-6C/Ly-6G-specific VHH immunotoxin to granulocytes and monocytes, granulocytes were significantly more sensitive than monocytes to immunotoxins treatment. Our results illustrate the need of early, thorough in vivo characterization of ADC candidates.

Original languageEnglish (US)
Article number17916
JournalScientific Reports
Volume7
Issue number1
DOIs
StatePublished - Dec 1 2017
Externally publishedYes

Fingerprint

Immunotoxins
Myeloid Cells
Epitopes
Antibodies
Granulocytes
Monocytes
Pharmaceutical Preparations
Autoimmune Diseases
Apoptosis
Antigens
Neoplasms

ASJC Scopus subject areas

  • General

Cite this

The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent. / Bachran, Christopher; Schröder, Matthias; Conrad, Lena; Cragnolini, Juan J.; Tafesse, Fikadu; Helming, Laura; Ploegh, Hidde L.; Swee, Lee Kim.

In: Scientific Reports, Vol. 7, No. 1, 17916, 01.12.2017.

Research output: Contribution to journalArticle

Bachran, C, Schröder, M, Conrad, L, Cragnolini, JJ, Tafesse, F, Helming, L, Ploegh, HL & Swee, LK 2017, 'The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent', Scientific Reports, vol. 7, no. 1, 17916. https://doi.org/10.1038/s41598-017-17948-0
Bachran, Christopher ; Schröder, Matthias ; Conrad, Lena ; Cragnolini, Juan J. ; Tafesse, Fikadu ; Helming, Laura ; Ploegh, Hidde L. ; Swee, Lee Kim. / The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{21e5ddf9db4a4590ae03bf05a4da2a1e,
title = "The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent",
abstract = "The central role of myeloid cells in driving autoimmune diseases and cancer has raised interest in manipulating their function or depleting them for therapeutic benefits. To achieve this, antibodies are used to antagonize differentiation, survival and polarization signals or to kill target cells, for example in the form of antibody-drug conjugates (ADC). The action of ADC in vivo can be hard to predict based on target expression pattern alone. The biology of the targeted receptor as well as its interplay with the ADC can have drastic effects on cell apoptosis versus survival. Here we investigated the efficacy of CD11b or Ly-6C/Ly-6G-specific variable fragments of camelid heavy chain-only antibodies (VHH) conjugated to Pseudomonas exotoxin A to deplete myeloid cells in vitro and in vivo. Our data highlight striking differences in cell killing in vivo, depending on the cell subset and organs targeted, but not antigen expression level or VHH affinity. We observed striking differences in depletion efficiency of monocytes versus granulocytes in mice. Despite similar binding of Ly-6C/Ly-6G-specific VHH immunotoxin to granulocytes and monocytes, granulocytes were significantly more sensitive than monocytes to immunotoxins treatment. Our results illustrate the need of early, thorough in vivo characterization of ADC candidates.",
author = "Christopher Bachran and Matthias Schr{\"o}der and Lena Conrad and Cragnolini, {Juan J.} and Fikadu Tafesse and Laura Helming and Ploegh, {Hidde L.} and Swee, {Lee Kim}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-17948-0",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent

AU - Bachran, Christopher

AU - Schröder, Matthias

AU - Conrad, Lena

AU - Cragnolini, Juan J.

AU - Tafesse, Fikadu

AU - Helming, Laura

AU - Ploegh, Hidde L.

AU - Swee, Lee Kim

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The central role of myeloid cells in driving autoimmune diseases and cancer has raised interest in manipulating their function or depleting them for therapeutic benefits. To achieve this, antibodies are used to antagonize differentiation, survival and polarization signals or to kill target cells, for example in the form of antibody-drug conjugates (ADC). The action of ADC in vivo can be hard to predict based on target expression pattern alone. The biology of the targeted receptor as well as its interplay with the ADC can have drastic effects on cell apoptosis versus survival. Here we investigated the efficacy of CD11b or Ly-6C/Ly-6G-specific variable fragments of camelid heavy chain-only antibodies (VHH) conjugated to Pseudomonas exotoxin A to deplete myeloid cells in vitro and in vivo. Our data highlight striking differences in cell killing in vivo, depending on the cell subset and organs targeted, but not antigen expression level or VHH affinity. We observed striking differences in depletion efficiency of monocytes versus granulocytes in mice. Despite similar binding of Ly-6C/Ly-6G-specific VHH immunotoxin to granulocytes and monocytes, granulocytes were significantly more sensitive than monocytes to immunotoxins treatment. Our results illustrate the need of early, thorough in vivo characterization of ADC candidates.

AB - The central role of myeloid cells in driving autoimmune diseases and cancer has raised interest in manipulating their function or depleting them for therapeutic benefits. To achieve this, antibodies are used to antagonize differentiation, survival and polarization signals or to kill target cells, for example in the form of antibody-drug conjugates (ADC). The action of ADC in vivo can be hard to predict based on target expression pattern alone. The biology of the targeted receptor as well as its interplay with the ADC can have drastic effects on cell apoptosis versus survival. Here we investigated the efficacy of CD11b or Ly-6C/Ly-6G-specific variable fragments of camelid heavy chain-only antibodies (VHH) conjugated to Pseudomonas exotoxin A to deplete myeloid cells in vitro and in vivo. Our data highlight striking differences in cell killing in vivo, depending on the cell subset and organs targeted, but not antigen expression level or VHH affinity. We observed striking differences in depletion efficiency of monocytes versus granulocytes in mice. Despite similar binding of Ly-6C/Ly-6G-specific VHH immunotoxin to granulocytes and monocytes, granulocytes were significantly more sensitive than monocytes to immunotoxins treatment. Our results illustrate the need of early, thorough in vivo characterization of ADC candidates.

UR - http://www.scopus.com/inward/record.url?scp=85038638084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038638084&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-17948-0

DO - 10.1038/s41598-017-17948-0

M3 - Article

AN - SCOPUS:85038638084

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 17916

ER -